Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immune Checkpoint Blockade Delays Cancer Development and Extends Survival in DNA Polymerase Mutator Syndromes

30 Dec 2024

Abstract excerpt

Mutations in the exonuclease domains of the replicative nuclear DNA polymerases POLD1 and POLE are associated with increased cancer incidence, elevated tumor mutation burden (TMB), and enhanced response to immune checkpoint blockade (ICB). Although ICB is approved for treatment of several cancers, not all tumors with elevated TMB respond, highlighting the need for a better understanding of how TMB affects tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Cancer Immunotherapy and Biomarkers
Share to Epigenetics and DNA Methylation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39786467
DOI: 10.1158/0008-5472.can-24-2589

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immune Checkpoint Blockade Delays Cancer Development and Extends Survival in DNA Polymerase Mutator SyndromesPMID 39786467Read ↗

Immune Checkpoint Blockade Delays Cancer and Extends Survival in Murine DNA Polymerase Mutator SyndromesSemantic proximity Read ↗

Cancers from Novel Pole-Mutant Mouse Models Provide Insights into Polymerase-Mediated Hypermutagenesis and Immune Checkpoint Blockade.Semantic proximity Read ↗

Dissecting the Functional Significance of DNA Polymerase Mutations in Cancer.Semantic proximity Read ↗

Immune checkpoint inhibitors in POLE/POLD1 proofreading-deficient CRC: from molecular basis to clinical practice and future directions.Semantic proximity Read ↗

Beyond proofreading: POLD1 mutations as dynamic orchestrators of genomic instability and immune evasion in cancerSemantic proximity Read ↗

Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.Semantic proximity Read ↗

Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity.Semantic proximity Read ↗

POLE/POLD1 mutation and tumor immunotherapy.Semantic proximity Read ↗

High incidence of epithelial cancers in mice deficient for DNA polymerase delta proofreading.Semantic proximity Read ↗

Distinctive genomic characteristics in POLE/POLD1-mutant cancers can potentially predict beneficial clinical outcomes in patients who receive immune checkpoint inhibitorSemantic proximity Read ↗

Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden.Semantic proximity Read ↗

Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.